Editor's Note: the "Trending USA Stocks" column tracks the day's top bullish stocks in the USA market, aiding investors in promptly identifying opportunities for potential gains.

21/01/2025 Eastern Time in USA The Dow Jones Industrial Average rose by 1.24%, closing at 44025.81 points; the Nasdaq Composite rose by 0.64%, closing at 19756.78 points; the S&P 500 Index rose by 0.88%, closing at 6049.24 points. 

Sahm has compiled the Top 10 Daily Stock Price Gainers in the USA market.

INNOVATE Corp. Common Stock: Overnight gain 86.3%, FDA approval for MediBeacon's kidney function test boosts market optimism and stock performance.

INNOVATE Corp. (NYSE: VATE), established in 1994, is a diversified infrastructure and communications services provider primarily serving clients in Canada and the United States. The company offers a comprehensive suite of services, encompassing voice, wireless, internet, VoIP, data, hosting, and data center solutions. The firm's operations are structured into three primary segments: Growth Services, Legacy Services, and ICS. These segments are managed through three key divisions: North American Telecom, BLACKIRON Data, and ICS. INNOVATE Corp.'s core market is centered in Canada, with its principal reportable business units being North American Telecom and BLACKIRON Data. These divisions drive the company's revenue and operational focus in the telecommunications and data services sectors. As a leading player in the infrastructure and communications industry, INNOVATE Corp. continues to leverage its extensive network and technological capabilities to meet the evolving needs of its diverse client base across North America.

INNOVATE Corp. Common Stock(VATE.US) experienced a significant surge in stock price following the FDA approval of its subsidiary MediBeacon's TGFR system for assessing kidney function in patients with normal or impaired renal function. The system demonstrated impressive clinical trial results, achieving a P30 value of 94%, indicating high accuracy and broad applicability. This breakthrough opens new opportunities for INNOVATE Corp. in the kidney function testing market, potentially generating substantial revenue. Market optimism regarding the company's prospects drove VATE shares up 86.3% overnight, bringing the year-to-date gain to 92.7%. The company's current market capitalization stands at $126 million. This development marks a pivotal moment for INNOVATE Corp., positioning it as a key player in the renal diagnostics sector.

U.S. Energy Corp.: Overnight gain 63.4%, Strong market performance and strategic positioning drive stock surge despite losses

U.S. Energy Corp. (NASDAQ: USEG), a veteran independent energy company established in 1966, focuses on the acquisition and development of oil, natural gas, and other mineral resources within the United States. The company's primary operations are concentrated in key energy-producing regions, including the Rocky Mountains, Louisiana, and Texas. The firm's strategic objectives encompass enhancing production volumes, expanding reserves, boosting revenue streams, and optimizing cash flow, while maintaining a disciplined approach to debt management. In a move to align with its evolving business needs, U.S. Energy Corp. relocated its state of incorporation from Wyoming to Delaware in 2022. As an established player in the domestic energy sector, U.S. Energy Corp. continues to leverage its expertise in resource exploration and development, positioning itself to capitalize on opportunities in the dynamic U.S. energy landscape. The company's focus on strategic acquisitions and operational efficiency underscores its commitment to creating long-term shareholder value in the competitive energy market.

U.S. Energy Corp.(USEG.US) experienced a significant surge in stock price, driven by multiple factors. The company's shares skyrocketed 63.4% overnight, bringing the year-to-date gain to an impressive 132.5%, demonstrating robust market performance. Despite reporting a net loss of $2.25 million in its latest financial results, two analyst firms maintain a unanimous "Buy" rating, reflecting investor optimism about the company's future prospects. USEG's strategic focus on oil and gas development in South Texas and North Dakota's Williston Basin is viewed favorably for long-term growth. Furthermore, the increased trading volume of 86,539 shares and a turnover rate of 0.31% indicate heightened market interest, contributing to the stock's upward momentum. These factors collectively underscore the positive sentiment surrounding U.S. Energy Corp.'s market position and growth potential.

Rigetti Computing Inc Ordinary Shares: Overnight gain 42.2%, Quantum computing stocks rebound; Microsoft's optimistic outlook boosts investor confidence in sector.

Rigetti Computing Inc., a Delaware-based corporation, is at the forefront of full-stack quantum computing technology. Since 2017, the company has been offering cloud-based quantum computing services, providing low-latency quantum-classical integrated solutions to clients worldwide through its proprietary platform. In a significant industry breakthrough, Rigetti developed the first multi-chip quantum processor, showcasing its innovative capabilities. The company designs and manufactures quantum chips at its in-house Fab-1 facility, which stands as the industry's first dedicated integrated quantum device manufacturing plant. This vertical integration underscores Rigetti's leadership position in quantum computing hardware. The company's end-to-end approach, from chip fabrication to cloud service delivery, positions Rigetti as a key player in the rapidly evolving quantum computing sector. As quantum technologies continue to advance, Rigetti's comprehensive capabilities and infrastructure investments may provide it with a competitive edge in this high-potential market.

Rigetti Computing Inc Ordinary Shares(RGTI.US) experienced a significant surge of 42.2% on Tuesday, driven by multiple factors. The rally came as part of a broader rebound in quantum computing stocks following Monday's sell-off, indicating a market correction. Microsoft's announcement that it is on the cusp of a reliable quantum computing era, with accelerated research and development expected in the next 12 months, bolstered investor confidence in the sector. Options trading data revealed a bullish sentiment, with call options accounting for 66.84% of total volume, substantially outweighing put options at 33.16%. Despite the day's gains, RGTI remains down 8.4% year-to-date, suggesting that the recent uptick is partially a recovery from previous losses. The stock's performance reflects both sector-wide trends and company-specific optimism in the quantum computing space.

Tempus AI: Overnight gain 35.5%, Pelosi's options purchase, acquisition plans, and AI market position boost investor confidence

Tempus AI, Inc., a pioneering artificial intelligence company in the healthcare sector, has been at the forefront of precision medicine since its inception in August 2015. The firm specializes in developing advanced AI-driven diagnostic systems, aiming to revolutionize the medical landscape. The company's core business model revolves around the integration of laboratory data with individual patient clinical information, enabling personalized and intelligent analysis of diagnostic results. This innovative approach is designed to significantly enhance the accuracy and efficiency of medical diagnoses, ultimately leading to more targeted treatment plans for patients. Tempus AI's cutting-edge technology has positioned the company as a key player in the burgeoning field of AI-assisted healthcare. By leveraging machine learning algorithms and big data analytics, the firm is working to unlock new possibilities in personalized medicine, potentially transforming patient outcomes across various medical disciplines. As the healthcare industry continues to evolve, Tempus AI remains committed to pushing the boundaries of what's possible in medical diagnostics and treatment planning. The company's ongoing research and development efforts underscore its dedication to improving patient care through the application of advanced artificial intelligence technologies.

The recent surge in Tempus AI(TEM.US) stock price can be attributed to multiple factors. Notably, former U.S. House Speaker Nancy Pelosi's purchase of call options in the company has been interpreted as a positive signal by investors. Additionally, Tempus AI's promising outlook in precision medicine, particularly with the impending acquisition of Ambry Genetics, is expected to bolster its competitiveness in hereditary cancer screening. The company's improved fourth-quarter financial performance, with revenue reaching $200 million and annual revenue of approximately $693 million, demonstrates robust business growth. Furthermore, TEM's 3.5% market share in the global medical technology AI sector underscores its established presence in this rapidly expanding industry.

The Top 10 Daily Gainers in the USA market are listed as follows:

Editor's note: This content was generated by Sahm's in-house AI-enabled SaaS tool and was reviewed by our editing team.